Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (November 2026)
15 slides from Aim Immunotech's investor presentation, Nov 5, 2026
Slide 1: The Ampligen Opportunity
The Ampligen Opportunity eo Q4 2026 oe
Slide 2: Forward Looking Statements
rN Forward Looking Statements Some of the statements included in this presentation are forward-looking statements and involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: Strategic objective: Prolong disease control
Strategic objective: Prolong disease control Evaluate Ampligen as an addition to daraxonrasib Can adding Ampligen sustain the clinical benefit achieved with daraxonrasib? Clinical goal Extend response duration and delay progression, including in patients with stable disease. Strategy to investigate
Slide 4: Daraxonrasib: Clinical advance and remaining need
Daraxonrasib: Clinical advance and remaining need RASolute 302: randomized phase 3 trial in previously treated metastatic PDAC Overall population: daraxonrasib (n=248) vs investigator-choice chemotherapy (n=252) Median progression-free survival Median overall survival 7.2 vs 3.6 months 13.2 vs 6.7 m
Slide 5: Daraxonrasib + Ampligen: Scientific rationale
Daraxonrasib + Ampligen: Scientific rationale Complementary mechanisms may suggest possibility of more durable tumor control Daraxonrasib Ampligen (rintatolimod) RAS(ON) inhibition TLR3-mediated immune stimulation Targets tumor-driving RAS signaling. May strengthen dendritic-cell and T-cell response
Slide 6: AMP-NPP
AMP-NPP Netherlands government-approved Named Patient Program Administering Ampligen as a Monotherapy Following SOC Chemotherapy 57 Single-arm Named Patient Program with a historical-control comparison Statistically signi improved Overall Survival and Su bjects with os 7 Progression-Free Survivalin
Slide 7: AMP-NPP: Overall survival observations
AMP-NPP Exploratory and Statistically Significant Overall Survival Observations Following SOC Chemotherapy and Ampligen in Pancreatic Cancer — Ampligen (n=57) ~ Historical control (n=27) Median Overall Survival Months 100 Ampligen Historical Control 19.7 months 12.5 months 50 % Survival 0 20 40 60 8
Slide 8: AMP-NPP: Progression-free survival observations
AMP-NPP Exploratory and Statistically Significant Progression-free Survival Observations Following SOC Chemotherapy and Ampligen in Pancreatic Cancer — Ampligen (n=57) + Historical control (n=27) ( ) Median Progression-free Survival Months 100 Ampligen Historical Control 12.6 months 8.6 months 50 %
Slide 9: AMP-NPP: Neutrophil-to-lymphocyte ratio and survival
AMP-NPP Lower Baseline Neutrophil-to-Lymphocyte Ratios Were Associated With Statistically Significant Improvement in Survival in Ampligen-Treated Patients 100 NIL <= 4.5 (n=39) + NIL > 4.5 (n=9) Median Overall Survival 3 ~ Historical control (n=27) Months 2 z a 50 N/L<=4.5 N/L>4.5 xe 34.8 months 19.
Slide 10: DURIPANC: Phase 1/2 trial design
DURIPANC Ongoing Phase 1/2 Clinical Trial of Ampligen Following Chemotherapy in Metastatic Pancreatic Cancer Phase 2 Primary Endpoint Single treatment arm DURIPANG Clinical benefit rate at 24 weeks Total ENROLLMENT Hy (measured from start of combo Ampligen therapy) Stable disease, partial 28 subject
Slide 11: DURIPANC: Interim tolerability and quality of life
DURIPANC Interim Results (as of June 2, 2026) Show Encouraging Tolerability and Consistently High Quality of Life Interim observations with Ampligen + durvalumab following FOLFIRINOX Manageable ‘ Safety Profile Only three grade 3 immune-related adverse events reported Patient-Reported Patient evalua
Slide 12: DURIPANC: Interim immune activation observations
DURIPANC Interim observations of immune activation with Ampligen + durvalumab following FOLFIRINOX iG Q Early Immune Findings going Evaluation Initial profiling suggests coordinated activation ofinnate and Paired tumor biopsies and longitudinal blood analyses are adaptive immune responses underway E
Slide 13: DURIPANC Results Expected to Inform Phase 3 Design
DURIPANC DURIPANC Results Expected to Inform the Design of Potential Pivotal Phase 3 Trial 1 Wd Phase 1 Complete 2 Wf Enrollment Complete Safety run-in supported Final patient dosed, as reported in progression to Phase 2 the June 2026 corporate update 3 Topline Results 4 Secondary Endpoint Analysis
Slide 14: The AIM Investment Case — Why AIM and why now?
The AIM Investment Case — “Why AIM and why now?” Ampligen as a Monotherapy Linked to Statistically Significant Survival Results and Improved Quality of Life Upcoming Study Data and Analyses May Provide Important Indication of the Potential for Combination Therapy of Ampligen and Durvalumab to Extend
Slide 15: Thank You!
NYSE American: AIM aimimmuno.com ImmunoTech Thank You! : rae ean a La
AIM ImmunoTech — Investor Presentation (November 2026) on 6ix